Once-weekly dosing of Kyprolis improves PFS vs. twice-weekly option

Amgen Inc. (NASDAQ:AMGN) reported interim data from the Phase III ARROW trial in 478 patients with relapsed and refractory multiple myeloma

Read the full 213 word article

User Sign In